Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca

by

  1. Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial AstraZeneca
  2. AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression Seeking Alpha
  3. Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
  4. AstraZeneca’s Tagrisso, chemo combination shows promise in lung cancer trial Reuters
  5. Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC OncLive
  6. View Full Coverage on Google News

Read original article here

Leave a Comment